APO Research
Talk to an analyst

APO RESEARCH · REPORT

Microbiome CDMO

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Microbiome CDMO Market Analysis and Forecast 2026-2032

1 January 2026190 pages

Choose your research edition.

Industry ResearchMicrobiome CDMO Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Microbiome CDMO Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Microbiome CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Microbiome CDMO Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Microbiome CDMO Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Microbiome CDMO market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Microbiome CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Microbiome CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Microbiome CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Microbiome CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Microbiome CDMO include Arranta Bio, Wacker Chemie AG, Bactera, SGS Quay Pharma, Biose, EnteroBiotix, Genome And Company, Lallemand Health Solutions and List Bio, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Microbiome CDMO, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Microbiome CDMO, also provides the revenue of main regions and countries. Of the upcoming market potential for Microbiome CDMO, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Microbiome CDMO revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Microbiome CDMO market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Microbiome CDMO revenue, projected growth trends, production technology, application and end-user industry.

Microbiome CDMO Segment by Company

Arranta Bio

Wacker Chemie AG

Bactera

SGS Quay Pharma

Biose

EnteroBiotix

Genome And Company

Lallemand Health Solutions

List Bio

Rise BioServices

Lonza

MaaT Pharma

NIZO

Quay Pharmaceuticals

Recipharm

Microbiome CDMO Segment by Type

Microbial CDMO

Antibiotic CDMO

Phage CDMO

Bacteriocins CDMO

Microbiome CDMO Segment by Application

Vaccine R&D

Biopharmaceutical

Cell Therapy

Others

Microbiome CDMO Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Microbiome CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Microbiome CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Microbiome CDMO.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Microbiome CDMO in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Microbiome CDMO company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Microbiome CDMO revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Microbiome CDMO Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Microbial CDMO Major Player Table 3. Antibiotic CDMO Major Player Table 4. Phage CDMO Major Player Table 5. Bacteriocins CDMO Major Player Table 6. Global Microbiome CDMO Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Vaccine R&D Major Player Table 8. Biopharmaceutical Major Player Table 9. Cell Therapy Major Player Table 10. Others Major Player Table 11. Microbiome CDMO Industry Trends Table 12. Microbiome CDMO Industry Drivers Table 13. Microbiome CDMO Industry Opportunities and Challenges Table 14. Microbiome CDMO Industry Restraints Table 15. Global Microbiome CDMO Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Microbiome CDMO Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Microbiome CDMO Market Share by Region (2021-2026) Table 18. Global Microbiome CDMO Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Microbiome CDMO Market Share by Region (2027-2032) Table 20. Global Microbiome CDMO Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Microbiome CDMO Revenue Market Share by Players (2021-2026) Table 22. Global Microbiome CDMO Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Microbiome CDMO Key Players Headquarters & Area Served Table 24. Global Microbiome CDMO Players, Product Type & Application Table 25. Global Microbiome CDMO Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Microbiome CDMO by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Microbiome CDMO Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Microbiome CDMO Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Microbiome CDMO Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Microbiome CDMO Revenue Market Share by Type (2021-2026) Table 32. Global Microbiome CDMO Revenue Market Share by Type (2027-2032) Table 33. Global Microbiome CDMO Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Microbiome CDMO Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Microbiome CDMO Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Microbiome CDMO Revenue Market Share by Application (2021-2026) Table 37. Global Microbiome CDMO Revenue Market Share by Application (2027-2032) Table 38. Arranta Bio Company Information Table 39. Arranta Bio Business Overview Table 40. Arranta Bio Microbiome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Arranta Bio Microbiome CDMO Product Portfolio Table 42. Arranta Bio Recent Development Table 43. Wacker Chemie AG Company Information Table 44. Wacker Chemie AG Business Overview Table 45. Wacker Chemie AG Microbiome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Wacker Chemie AG Microbiome CDMO Product Portfolio Table 47. Wacker Chemie AG Recent Development Table 48. Bactera Company Information Table 49. Bactera Business Overview Table 50. Bactera Microbiome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. Bactera Microbiome CDMO Product Portfolio Table 52. Bactera Recent Development Table 53. SGS Quay Pharma Company Information Table 54. SGS Quay Pharma Business Overview Table 55. SGS Quay Pharma Microbiome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. SGS Quay Pharma Microbiome CDMO Product Portfolio Table 57. SGS Quay Pharma Recent Development Table 58. Biose Company Information Table 59. Biose Business Overview Table 60. Biose Microbiome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. Biose Microbiome CDMO Product Portfolio Table 62. Biose Recent Development Table 63. EnteroBiotix Company Information Table 64. EnteroBiotix Business Overview Table 65. EnteroBiotix Microbiome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. EnteroBiotix Microbiome CDMO Product Portfolio Table 67. EnteroBiotix Recent Development Table 68. Genome And Company Company Information Table 69. Genome And Company Business Overview Table 70. Genome And Company Microbiome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. Genome And Company Microbiome CDMO Product Portfolio Table 72. Genome And Company Recent Development Table 73. Lallemand Health Solutions Company Information Table 74. Lallemand Health Solutions Business Overview Table 75. Lallemand Health Solutions Microbiome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. Lallemand Health Solutions Microbiome CDMO Product Portfolio Table 77. Lallemand Health Solutions Recent Development Table 78. List Bio Company Information Table 79. List Bio Business Overview Table 80. List Bio Microbiome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. List Bio Microbiome CDMO Product Portfolio Table 82. List Bio Recent Development Table 83. Rise BioServices Company Information Table 84. Rise BioServices Business Overview Table 85. Rise BioServices Microbiome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 86. Rise BioServices Microbiome CDMO Product Portfolio Table 87. Rise BioServices Recent Development Table 88. Lonza Company Information Table 89. Lonza Business Overview Table 90. Lonza Microbiome CDMO Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Lonza Microbiome CDMO Product Portfolio Table 92. Lonza Recent Development Table 93. MaaT Pharma Company Information Table 94. MaaT Pharma Business Overview Table 95. MaaT Pharma Microbiome CDMO Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. MaaT Pharma Microbiome CDMO Product Portfolio Table 97. MaaT Pharma Recent Development Table 98. NIZO Company Information Table 99. NIZO Business Overview Table 100. NIZO Microbiome CDMO Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. NIZO Microbiome CDMO Product Portfolio Table 102. NIZO Recent Development Table 103. Quay Pharmaceuticals Company Information Table 104. Quay Pharmaceuticals Business Overview Table 105. Quay Pharmaceuticals Microbiome CDMO Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Quay Pharmaceuticals Microbiome CDMO Product Portfolio Table 107. Quay Pharmaceuticals Recent Development Table 108. Recipharm Company Information Table 109. Recipharm Business Overview Table 110. Recipharm Microbiome CDMO Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Recipharm Microbiome CDMO Product Portfolio Table 112. Recipharm Recent Development Table 113. North America Microbiome CDMO Revenue by Type (2021-2026) & (US$ Million) Table 114. North America Microbiome CDMO Revenue by Type (2027-2032) & (US$ Million) Table 115. North America Microbiome CDMO Revenue by Application (2021-2026) & (US$ Million) Table 116. North America Microbiome CDMO Revenue by Application (2027-2032) & (US$ Million) Table 117. North America Microbiome CDMO Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 118. North America Microbiome CDMO Revenue by Country (2021-2026) & (US$ Million) Table 119. North America Microbiome CDMO Revenue by Country (US$ Million) & (2027-2032) Table 120. Europe Microbiome CDMO Revenue by Type (2021-2026) & (US$ Million) Table 121. Europe Microbiome CDMO Revenue by Type (2027-2032) & (US$ Million) Table 122. Europe Microbiome CDMO Revenue by Application (2021-2026) & (US$ Million) Table 123. Europe Microbiome CDMO Revenue by Application (2027-2032) & (US$ Million) Table 124. Europe Microbiome CDMO Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 125. Europe Microbiome CDMO Revenue by Country (2021-2026) & (US$ Million) Table 126. Europe Microbiome CDMO Revenue by Country (US$ Million) & (2027-2032) Table 127. China Microbiome CDMO Revenue by Type (2021-2026) & (US$ Million) Table 128. China Microbiome CDMO Revenue by Type (2027-2032) & (US$ Million) Table 129. China Microbiome CDMO Revenue by Application (2021-2026) & (US$ Million) Table 130. China Microbiome CDMO Revenue by Application (2027-2032) & (US$ Million) Table 131. Asia Microbiome CDMO Revenue by Type (2021-2026) & (US$ Million) Table 132. Asia Microbiome CDMO Revenue by Type (2027-2032) & (US$ Million) Table 133. Asia Microbiome CDMO Revenue by Application (2021-2026) & (US$ Million) Table 134. Asia Microbiome CDMO Revenue by Application (2027-2032) & (US$ Million) Table 135. Asia Microbiome CDMO Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 136. Asia Microbiome CDMO Revenue by Region (US$ Million) & (2021-2026) Table 137. Asia Microbiome CDMO Revenue by Region (US$ Million) & (2027-2032) Table 138. SAMEA Microbiome CDMO Revenue by Type (2021-2026) & (US$ Million) Table 139. SAMEA Microbiome CDMO Revenue by Type (2027-2032) & (US$ Million) Table 140. SAMEA Microbiome CDMO Revenue by Application (2021-2026) & (US$ Million) Table 141. SAMEA Microbiome CDMO Revenue by Application (2027-2032) & (US$ Million) Table 142. SAMEA Microbiome CDMO Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 143. SAMEA Microbiome CDMO Revenue by Country (2021-2026) & (US$ Million) Table 144. SAMEA Microbiome CDMO Revenue by Country (US$ Million) & (2027-2032) Table 145. Research Programs/Design for This Report Table 146. Authors List of This Report Table 147. Secondary Sources Table 148. Primary Sources List of Figures Figure 1. Microbiome CDMO Image Figure 2. Global Microbiome CDMO Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Microbiome CDMO Market Size Share 2021 VS 2025 VS 2032 Figure 4. Microbial CDMO Image Figure 5. Antibiotic CDMO Image Figure 6. Phage CDMO Image Figure 7. Bacteriocins CDMO Image Figure 8. Global Microbiome CDMO Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Microbiome CDMO Market Size Share 2021 VS 2025 VS 2032 Figure 10. Vaccine R&D Image Figure 11. Biopharmaceutical Image Figure 12. Cell Therapy Image Figure 13. Others Image Figure 14. Global Microbiome CDMO Market Size (US$ Million) & (2021-2032) Figure 15. Global Microbiome CDMO Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Microbiome CDMO Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Microbiome CDMO Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Microbiome CDMO Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Microbiome CDMO Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Microbiome CDMO Revenue Market Share by Type (2021-2032) Figure 22. Global Microbiome CDMO Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Microbiome CDMO Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Microbiome CDMO Revenue Market Share by Application (2021-2032) Figure 25. North America Microbiome CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Microbiome CDMO Revenue Share by Type (2021-2032) Figure 27. North America Microbiome CDMO Revenue Share by Application (2021-2032) Figure 28. North America Microbiome CDMO Revenue Share by Country (2021-2032) Figure 29. United States Microbiome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Microbiome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Microbiome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Microbiome CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Microbiome CDMO Revenue Share by Type (2021-2032) Figure 34. Europe Microbiome CDMO Revenue Share by Application (2021-2032) Figure 35. Europe Microbiome CDMO Revenue Share by Country (2021-2032) Figure 36. Germany Microbiome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Microbiome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Microbiome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Microbiome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Microbiome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Microbiome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Microbiome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Microbiome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Microbiome CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Microbiome CDMO Revenue Share by Type (2021-2032) Figure 46. China Microbiome CDMO Revenue Share by Application (2021-2032) Figure 47. Asia Microbiome CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Microbiome CDMO Revenue Share by Type (2021-2032) Figure 49. Asia Microbiome CDMO Revenue Share by Application (2021-2032) Figure 50. Asia Microbiome CDMO Revenue Share by Region (2021-2032) Figure 51. Japan Microbiome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Microbiome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Microbiome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Microbiome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Microbiome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Microbiome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Microbiome CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Microbiome CDMO Revenue Share by Type (2021-2032) Figure 59. SAMEA Microbiome CDMO Revenue Share by Application (2021-2032) Figure 60. SAMEA Microbiome CDMO Revenue Share by Country (2021-2032) Figure 61. Brazil Microbiome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Microbiome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Microbiome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Microbiome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Microbiome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Microbiome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Microbiome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Microbiome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Microbiome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Microbiome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Microbiome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Microbial CDMO
  • Antibiotic CDMO
  • Phage CDMO
  • Bacteriocins CDMO
Applications
  • Vaccine R&D
  • Biopharmaceutical
  • Cell Therapy
  • Others
Companies covered
  • Arranta Bio
  • Wacker Chemie AG
  • Bactera
  • SGS Quay Pharma
  • Biose
  • EnteroBiotix
  • Genome And Company
  • Lallemand Health Solutions
  • List Bio
  • Rise BioServices
  • Lonza
  • MaaT Pharma
  • NIZO
  • Quay Pharmaceuticals
  • Recipharm

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Microbiome CDMO Market by Type
  3. 1.2.1 Global Microbiome CDMO Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Microbial CDMO
  5. 1.2.3 Antibiotic CDMO
  6. 1.2.4 Phage CDMO
  7. 1.2.5 Bacteriocins CDMO
  8. 1.3 Microbiome CDMO Market by Application
  9. 1.3.1 Global Microbiome CDMO Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Vaccine R&D
  11. 1.3.3 Biopharmaceutical
  12. 1.3.4 Cell Therapy
  13. 1.3.5 Others
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Microbiome CDMO Market Dynamics
  1. 2.1 Microbiome CDMO Industry Trends
  2. 2.2 Microbiome CDMO Industry Drivers
  3. 2.3 Microbiome CDMO Industry Opportunities and Challenges
  4. 2.4 Microbiome CDMO Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Microbiome CDMO Market Perspective (2021-2032)
  2. 3.2 Global Microbiome CDMO Growth Trends by Region
  3. 3.2.1 Global Microbiome CDMO Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Microbiome CDMO Market Size by Region (2021-2026)
  5. 3.2.3 Global Microbiome CDMO Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Microbiome CDMO Revenue by Players
  2. 4.1.1 Global Microbiome CDMO Revenue by Players (2021-2026)
  3. 4.1.2 Global Microbiome CDMO Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Microbiome CDMO Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Microbiome CDMO Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Microbiome CDMO Key Players Headquarters & Area Served
  7. 4.4 Global Microbiome CDMO Players, Product Type & Application
  8. 4.5 Global Microbiome CDMO Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Microbiome CDMO Market CR5 and HHI
  11. 4.6.3 2025 Microbiome CDMO Tier 1, Tier 2, and Tier 3
5 Microbiome CDMO Market Size by Type
  1. 5.1 Global Microbiome CDMO Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Microbiome CDMO Revenue by Type (2021-2032)
  3. 5.3 Global Microbiome CDMO Revenue Market Share by Type (2021-2032)
6 Microbiome CDMO Market Size by Application
  1. 6.1 Global Microbiome CDMO Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Microbiome CDMO Revenue by Application (2021-2032)
  3. 6.3 Global Microbiome CDMO Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Arranta Bio
  2. 7.1.1 Arranta Bio Company Information
  3. 7.1.2 Arranta Bio Business Overview
  4. 7.1.3 Arranta Bio Microbiome CDMO Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Arranta Bio Microbiome CDMO Product Portfolio
  6. 7.1.5 Arranta Bio Recent Developments
  7. 7.2 Wacker Chemie AG
  8. 7.2.1 Wacker Chemie AG Company Information
  9. 7.2.2 Wacker Chemie AG Business Overview
  10. 7.2.3 Wacker Chemie AG Microbiome CDMO Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Wacker Chemie AG Microbiome CDMO Product Portfolio
  12. 7.2.5 Wacker Chemie AG Recent Developments
  13. 7.3 Bactera
  14. 7.3.1 Bactera Company Information
  15. 7.3.2 Bactera Business Overview
  16. 7.3.3 Bactera Microbiome CDMO Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Bactera Microbiome CDMO Product Portfolio
  18. 7.3.5 Bactera Recent Developments
  19. 7.4 SGS Quay Pharma
  20. 7.4.1 SGS Quay Pharma Company Information
  21. 7.4.2 SGS Quay Pharma Business Overview
  22. 7.4.3 SGS Quay Pharma Microbiome CDMO Revenue and Gross Margin (2021-2026)
  23. 7.4.4 SGS Quay Pharma Microbiome CDMO Product Portfolio
  24. 7.4.5 SGS Quay Pharma Recent Developments
  25. 7.5 Biose
  26. 7.5.1 Biose Company Information
  27. 7.5.2 Biose Business Overview
  28. 7.5.3 Biose Microbiome CDMO Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Biose Microbiome CDMO Product Portfolio
  30. 7.5.5 Biose Recent Developments
  31. 7.6 EnteroBiotix
  32. 7.6.1 EnteroBiotix Company Information
  33. 7.6.2 EnteroBiotix Business Overview
  34. 7.6.3 EnteroBiotix Microbiome CDMO Revenue and Gross Margin (2021-2026)
  35. 7.6.4 EnteroBiotix Microbiome CDMO Product Portfolio
  36. 7.6.5 EnteroBiotix Recent Developments
  37. 7.7 Genome And Company
  38. 7.7.1 Genome And Company Company Information
  39. 7.7.2 Genome And Company Business Overview
  40. 7.7.3 Genome And Company Microbiome CDMO Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Genome And Company Microbiome CDMO Product Portfolio
  42. 7.7.5 Genome And Company Recent Developments
  43. 7.8 Lallemand Health Solutions
  44. 7.8.1 Lallemand Health Solutions Company Information
  45. 7.8.2 Lallemand Health Solutions Business Overview
  46. 7.8.3 Lallemand Health Solutions Microbiome CDMO Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Lallemand Health Solutions Microbiome CDMO Product Portfolio
  48. 7.8.5 Lallemand Health Solutions Recent Developments
  49. 7.9 List Bio
  50. 7.9.1 List Bio Company Information
  51. 7.9.2 List Bio Business Overview
  52. 7.9.3 List Bio Microbiome CDMO Revenue and Gross Margin (2021-2026)
  53. 7.9.4 List Bio Microbiome CDMO Product Portfolio
  54. 7.9.5 List Bio Recent Developments
  55. 7.10 Rise BioServices
  56. 7.10.1 Rise BioServices Company Information
  57. 7.10.2 Rise BioServices Business Overview
  58. 7.10.3 Rise BioServices Microbiome CDMO Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Rise BioServices Microbiome CDMO Product Portfolio
  60. 7.10.5 Rise BioServices Recent Developments
  61. 7.11 Lonza
  62. 7.11.1 Lonza Company Information
  63. 7.11.2 Lonza Business Overview
  64. 7.11.3 Lonza Microbiome CDMO Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Lonza Microbiome CDMO Product Portfolio
  66. 7.11.5 Lonza Recent Developments
  67. 7.12 MaaT Pharma
  68. 7.12.1 MaaT Pharma Company Information
  69. 7.12.2 MaaT Pharma Business Overview
  70. 7.12.3 MaaT Pharma Microbiome CDMO Revenue and Gross Margin (2021-2026)
  71. 7.12.4 MaaT Pharma Microbiome CDMO Product Portfolio
  72. 7.12.5 MaaT Pharma Recent Developments
  73. 7.13 NIZO
  74. 7.13.1 NIZO Company Information
  75. 7.13.2 NIZO Business Overview
  76. 7.13.3 NIZO Microbiome CDMO Revenue and Gross Margin (2021-2026)
  77. 7.13.4 NIZO Microbiome CDMO Product Portfolio
  78. 7.13.5 NIZO Recent Developments
  79. 7.14 Quay Pharmaceuticals
  80. 7.14.1 Quay Pharmaceuticals Company Information
  81. 7.14.2 Quay Pharmaceuticals Business Overview
  82. 7.14.3 Quay Pharmaceuticals Microbiome CDMO Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Quay Pharmaceuticals Microbiome CDMO Product Portfolio
  84. 7.14.5 Quay Pharmaceuticals Recent Developments
  85. 7.15 Recipharm
  86. 7.15.1 Recipharm Company Information
  87. 7.15.2 Recipharm Business Overview
  88. 7.15.3 Recipharm Microbiome CDMO Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Recipharm Microbiome CDMO Product Portfolio
  90. 7.15.5 Recipharm Recent Developments
8 North America
  1. 8.1 North America Microbiome CDMO Revenue (2021-2032)
  2. 8.2 North America Microbiome CDMO Revenue by Type (2021-2032)
  3. 8.2.1 North America Microbiome CDMO Revenue by Type (2021-2026)
  4. 8.2.2 North America Microbiome CDMO Revenue by Type (2027-2032)
  5. 8.3 North America Microbiome CDMO Revenue Share by Type (2021-2032)
  6. 8.4 North America Microbiome CDMO Revenue by Application (2021-2032)
  7. 8.4.1 North America Microbiome CDMO Revenue by Application (2021-2026)
  8. 8.4.2 North America Microbiome CDMO Revenue by Application (2027-2032)
  9. 8.5 North America Microbiome CDMO Revenue Share by Application (2021-2032)
  10. 8.6 North America Microbiome CDMO Revenue by Country
  11. 8.6.1 North America Microbiome CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Microbiome CDMO Revenue by Country (2021-2026)
  13. 8.6.3 North America Microbiome CDMO Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Microbiome CDMO Revenue (2021-2032)
  2. 9.2 Europe Microbiome CDMO Revenue by Type (2021-2032)
  3. 9.2.1 Europe Microbiome CDMO Revenue by Type (2021-2026)
  4. 9.2.2 Europe Microbiome CDMO Revenue by Type (2027-2032)
  5. 9.3 Europe Microbiome CDMO Revenue Share by Type (2021-2032)
  6. 9.4 Europe Microbiome CDMO Revenue by Application (2021-2032)
  7. 9.4.1 Europe Microbiome CDMO Revenue by Application (2021-2026)
  8. 9.4.2 Europe Microbiome CDMO Revenue by Application (2027-2032)
  9. 9.5 Europe Microbiome CDMO Revenue Share by Application (2021-2032)
  10. 9.6 Europe Microbiome CDMO Revenue by Country
  11. 9.6.1 Europe Microbiome CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Microbiome CDMO Revenue by Country (2021-2026)
  13. 9.6.3 Europe Microbiome CDMO Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Microbiome CDMO Revenue (2021-2032)
  2. 10.2 China Microbiome CDMO Revenue by Type (2021-2032)
  3. 10.2.1 China Microbiome CDMO Revenue by Type (2021-2026)
  4. 10.2.2 China Microbiome CDMO Revenue by Type (2027-2032)
  5. 10.3 China Microbiome CDMO Revenue Share by Type (2021-2032)
  6. 10.4 China Microbiome CDMO Revenue by Application (2021-2032)
  7. 10.4.1 China Microbiome CDMO Revenue by Application (2021-2026)
  8. 10.4.2 China Microbiome CDMO Revenue by Application (2027-2032)
  9. 10.5 China Microbiome CDMO Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Microbiome CDMO Revenue (2021-2032)
  2. 11.2 Asia Microbiome CDMO Revenue by Type (2021-2032)
  3. 11.2.1 Asia Microbiome CDMO Revenue by Type (2021-2026)
  4. 11.2.2 Asia Microbiome CDMO Revenue by Type (2027-2032)
  5. 11.3 Asia Microbiome CDMO Revenue Share by Type (2021-2032)
  6. 11.4 Asia Microbiome CDMO Revenue by Application (2021-2032)
  7. 11.4.1 Asia Microbiome CDMO Revenue by Application (2021-2026)
  8. 11.4.2 Asia Microbiome CDMO Revenue by Application (2027-2032)
  9. 11.5 Asia Microbiome CDMO Revenue Share by Application (2021-2032)
  10. 11.6 Asia Microbiome CDMO Revenue by Country
  11. 11.6.1 Asia Microbiome CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Microbiome CDMO Revenue by Country (2021-2026)
  13. 11.6.3 Asia Microbiome CDMO Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Microbiome CDMO Revenue (2021-2032)
  2. 12.2 SAMEA Microbiome CDMO Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Microbiome CDMO Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Microbiome CDMO Revenue by Type (2027-2032)
  5. 12.3 SAMEA Microbiome CDMO Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Microbiome CDMO Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Microbiome CDMO Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Microbiome CDMO Revenue by Application (2027-2032)
  9. 12.5 SAMEA Microbiome CDMO Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Microbiome CDMO Revenue by Country
  11. 12.6.1 SAMEA Microbiome CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Microbiome CDMO Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Microbiome CDMO Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst